Anzeige
Mehr »
Samstag, 07.06.2025 - Börsentäglich über 12.000 News
Starke Zahlen: EBITDA bei 9 Mio.?€ - Startet jetzt die Neubewertung?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A11664 | ISIN: US03209R1032 | Ticker-Symbol: 29A
Tradegate
06.06.25 | 15:51
22,420 Euro
-1,71 % -0,390
1-Jahres-Chart
AMPHASTAR PHARMACEUTICALS INC Chart 1 Jahr
5-Tage-Chart
AMPHASTAR PHARMACEUTICALS INC 5-Tage-Chart
RealtimeGeldBriefZeit
22,53023,09006.06.
22,59023,03006.06.

Aktuelle News zur AMPHASTAR Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DoAmphastar auf Jefferies-Konferenz: Strategischer Fokus auf Wachstum1
MiAmphastar Pharmaceuticals, Inc. - 8-K, Current Report-
22.05.Amphastar Pharmaceuticals, Inc.: Amphastar Pharmaceuticals to Present at the Jefferies Global Healthcare Conference222RANCHO CUCAMONGA, CA / ACCESS Newswire / May 22, 2025 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, CFO and Jacob Liawatidewi, EVP of Corporate Administration, will...
► Artikel lesen
12.05.Amphastar stock rating cut to Neutral by JPMorgan9
09.05.Amphastar Pharmaceuticals, Inc.: Amphastar Pharmaceuticals to Present at the 2025 Bank of America Health Care Conference242RANCHO CUCAMONGA, CA / ACCESS Newswire / May 9, 2025 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, CFO and Dan Dischner, SVP of Corp. Communication, will be participating...
► Artikel lesen
08.05.Amphastar Pharmaceuticals, Inc. - 10-Q, Quarterly Report3
AMPHASTAR Aktie jetzt für 0€ handeln
08.05.Amphastar outlines key launches and product growth drivers for 20254
07.05.Amphastar Q2 2025 slides: strategic shift to proprietary drugs amid growth challenges3
07.05.Amphastar Pharmaceuticals, Inc. - 8-K, Current Report4
07.05.Amphastar Pharmaceuticals, Inc.: Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2025245Reports Net Revenues of $170.5 Million for the Three Months Ended March 31, 2025 RANCHO CUCAMONGA, CA / ACCESS Newswire / May 7, 2025 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) ("Amphastar" or...
► Artikel lesen
06.05.Earnings Outlook For Amphastar Pharma3
30.04.Amphastar Pharmaceuticals, Inc.: Amphastar Pharmaceuticals to Release First Quarter Earnings and Hold Conference Call on May 7th, 2025204RANCHO CUCAMONGA, CA / ACCESS Newswire / April 30, 2025 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the Company will release results for its first quarter of 2025 ended March 31,...
► Artikel lesen
03.04.Amphastar Pharmaceuticals, Inc.: Amphastar Pharmaceuticals to Present at the 24th Annual Needham Virtual Healthcare Conference260RANCHO CUCAMONGA, CA / ACCESS Newswire / April 3, 2025 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, CFO and Dan Dischner, SVP of Corp. Communication, will be participating...
► Artikel lesen
28.03.Amphastar Pharmaceuticals, Inc.: International Medication Systems, Ltd. Receives FDA's Drug Shortage Assistance Award1.559Recognized for contributions to address shortage of epinephrine injection, 0.1 mg/mL syringes RANCHO CUCAMONGA, CA / ACCESS Newswire / March 28, 2025 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH)...
► Artikel lesen
21.03.Amphastar stock target cut to $32 by Piper Sandler, maintains neutral2
05.03.Amphastar Pharmaceuticals, Inc.: Amphastar Pharmaceuticals to Present at the Barclays 27th Annual Global Healthcare Conference438RANCHO CUCAMONGA, CA / ACCESS Newswire / March 5, 2025 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, CFO and Tony Marrs, EVP of Regulatory Affairs and Clinical Operations...
► Artikel lesen
03.03.Amphastar Pharmaceuticals, Inc. - 10-K, Annual Report4
28.02.Specialty Pharma Amphastar Stock Falls On Lower Than Expected Q4 Earnings, Analyst Sees Competitive Headwinds10
27.02.Amphastar Pharmaceuticals, Inc.: Amphastar Pharmaceuticals Reports Financial Results for the Three Months and Full Year Ended December 31, 2024312Reports Net Revenues of $186.5 Million for the Three Months Ended December 31, 2024 RANCHO CUCAMONGA, CA / ACCESS Newswire / February 27, 2025 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) ("Amphastar"...
► Artikel lesen
27.02.Amphastar Pharmaceuticals, Inc. - 8-K, Current Report4
Weiter >>
30 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1